Daiichi Sankyo Says No Plans To Shut Ranbaxy Bulk Drug Plant In India
This article was originally published in PharmAsia News
Daiichi Sankyo says it has no plans to close the Ranbaxy Laboratories plant in India for manufacturing bulk drugs
You may also be interested in...
Roche's Actemra is a major player in this space, but Humanigen is looking to take it on directly.
DJO Global will buy Trilliant Surgical to further its ongoing expansion into the US foot and ankle market.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.